A number of studies highlighted the multiple roles of HDAC, suggesting it as a potential target for chemotherapy and establishing the basis for the development and use of HDAC inhibitors (HDACi) as co-adjuvant for many anticancer agents for treatment of NSCLC [191,192]. Here, HDAC9 is linked to non-small cell lung carcinoma.